– BELGIUM, Mont-Saint-Guibert – Celyad (Euronext Brussels / Paris, NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced the appointment of Debasish F. Roychowdhury as new independent non-executive director.
Dr. Roychowdhury is a medical oncologist with over 15 years of comprehensive pharmaceutical industry experience and 14 years of patient care and academic research. In the pharmaceutical industry, Debasish held multiple positions of growing responsibility respectively at Eli Lilly, GSK and Sanofi, with direct therapeutic area experience mostly in oncology and hematology. Based in Boston, Massachusetts, Debasish is now using his extensive experience and global network to advise companies, organizations, and institutions in the biomedical field.
Dr. Roychowdhury’s appointment was effective 21 August 2015. Debasish will be replacing Jean-Marc Heynderickx who stepped down from the Board.
Michel Lussier, Chairman of the Board for Celyad, said: “The addition of Dr. Roychowdhury to the board is another key step to strengthening the strategic advice for our business plans and adds a depth of experience in oncology to help us realize the potential of the Natural Killer Receptor CAR-T portfolio we recently acquired. Also, a special and warm thanks to Jean-Marc Heynderickx who provided us with his solid support and advice for growth over the last three years.”
Dr. Christian Homsy, CEO of Celyad, added: “Our intention is to fully execute our strategic plan quickly focused on areas that we believe have the highest potential and value to patients. Dr. Roychowdhury will be another key partner to advise us on how best to deliver our engineered cell therapies to patients.”
About Celyad
Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrollment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015.
Celyad’s ordinary shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD and Celyad’s American Depositary Shares are listed on the NASDAQ Global Market under the ticker symbol CYAD.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
